• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Protein Tyrosine Kinases: From Inhibitors to Useful Drugs

Protein Tyrosine Kinases: From Inhibitors to Useful Drugs

Hardcover

Series: Cancer Drug Discovery & Development

Medical ReferenceChemistry

ISBN10: 158829384X
ISBN13: 9781588293848
Publisher: Springer Nature
Published: Sep 1 2005
Pages: 290
Weight: 1.69
Height: 0.90 Width: 6.32 Depth: 9.30
Language: English
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec(TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating selective low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining on-target vs off-target effects of kinase inhibitors.

Also in

Medical Reference